Press Releases July 16, 2026 10:15 AM

IQM Quantum Computers Plc’s new shares subscribed for with warrants have been registered with the Finnish Trade Register

IQM Quantum Computers registers 577,237 new shares after warrant exercise by Kreos Capital

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
IQMX

IQM Quantum Computers Plc announced that Kreos Capital exercised all outstanding warrants issued under a financing arrangement, resulting in the subscription of 577,237 new shares. The shares have been registered with the Finnish Trade Register, increasing total shares to 263,039,597. The new shares will begin trading on Nasdaq Helsinki soon, maintaining IQM's position as the first publicly listed European quantum computing company on Nasdaq.

IQM Quantum Computers Plc’s new shares subscribed for with warrants have been registered with the Finnish Trade Register
IQMX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kreos Capital exercised all outstanding warrants for IQM, subscribing to 577,237 new shares through net exercise.
  • The aggregate subscription price is EUR 5,772.37, entering the company's reserve for invested unrestricted equity.
  • Total shares now stand at 263,039,597, with shares to be admitted on Nasdaq Helsinki alongside existing shares around July 20, 2026.
  • This transaction reflects continued investor interest and capital strengthening in the quantum computing sector.

IQM Quantum Computers Plc, Stock Exchange Release, July 16, 2026 at 17:15 (EEST)

A total of 577,237 new shares have been subscribed for with IQM Quantum Computers Plc’s (“IQM” or the “Company”) warrants. The warrants were exercised by Kreos Capital VII Aggregator SCSp (“Kreos”) to whom the warrants were issued in connection with a financing arrangement pursuant to a warrant agreement dated December 23, 2025.

Under the warrant agreement, the warrants entitled Kreos to subscribe for a maximum of 1,015,511 shares. Kreos exercised all outstanding warrants through a net exercise, whereby instead of paying the aggregate subscription price in cash, Kreos elected to receive a reduced number of shares. As a result, 577,237 new shares were issued to Kreos. The aggregate subscription price of EUR 5,772.37 (EUR 0.01 per share) will be entered in its entirety into the Company's reserve for invested unrestricted equity. Following this exercise of warrants, no warrants remain outstanding under the warrant agreement.

The new shares subscribed for with the warrants have been registered with the Finnish Trade Register today, July 16, 2026. As a result of the registration, the total number of IQM’s shares and votes is 263,039,597. The new shares confer shareholder rights on their holders from the date of registration. The new shares will be admitted to trading on the regulated market of Nasdaq Helsinki Ltd together with the pre-existing shares on or about July 20, 2026.

For further information, please contact:

Blair Robertson, Vice President, Strategy & Corporate Development

Investor Relations Officer

[email protected]

About IQM Quantum Computers

IQM Quantum Computers (Nasdaq: IQMX) is a global leader in superconducting quantum computers, delivering full-stack quantum systems and cloud platform access to enterprises, research institutions, universities, high-performance computing centers, and national laboratories worldwide. IQM’s on-premises deployment model gives customers direct ownership and control of their quantum infrastructure. Founded in 2018 and headquartered in Finland, with major operations in Munich, IQM employs over 400 people and operates across Europe, Asia, and North America. IQM is the first publicly listed European quantum company on Nasdaq Stock Market.


Risks

  • Future dilution risk was mitigated by full exercise of warrants, but new share issuance could impact existing shareholders' ownership percentage.
  • The quantum computing industry remains nascent with potential technological, commercial, and regulatory uncertainties affecting company growth.
  • Market reaction may remain muted as this is a routine financing activity without immediate impact on operations or revenues.

More from Press Releases

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call Jul 22, 2026 Prairie Operating Co. Announces Appointment of Jennifer M. Grigsby to Board of Directors Jul 22, 2026 BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 Jul 22, 2026 Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology Jul 22, 2026 Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change Jul 22, 2026